Table 1.
Summary data of bone marrow harvests for GT
| Disease | Age at GT (years) | Weight (kg) | Harvested volume (ml) | Volume/kg | Collected TNC (×108)/kg | CD34+ (%) | Collected CD34+ cells (×106)/kg | Selected CD34+ cells (×106)/kg | Infused CD34+ cells (×106)/kg |
|---|---|---|---|---|---|---|---|---|---|
| ADA-SCID (n = 23) | 1.7 (0.5–6.0) | 10.1 (5.9–26.5) | 303.0 (190.0–1167.5) | 31.2 (14.2–48.6) | 4.2 (2.9–6.8) | 5.7 (2.0–6.7)a | 28.9 (9.8–43.1)a | 13.8 (4.4–22.9) | 10.7 (3.7–19.7) |
| WAS (n = 6) | 2.1 (0.9–6.0) | 12.7 (8.0–26.3) | 424.3 (275.0–773.0) | 34.2 (29.4–36.5) | 5.7 (3.5–6.6) | 2.9 (1.8–5.2) | 15.8 (10.8–18.7) | 9.1 (4.5–14.5) | 9.0 (3.7–14.1) |
| MLD (n = 28) | 1.3 (0.5–11.4) | 11 (7.3–25.3) | 420.0 (194.0–1132.0) | 36.9 (17.6–56.6) | 6.3 (3.4–9.4) | 3.0 (1.0–7.7) | 16.3 (5.6–65.9) | 9.6 (3.9–34.7) | 10.3 (3.8–25.9) |
| Total (n = 57) | 1.5 (0.5–11.4) | 10.6 (5.9–26.5) | 348.0 (190.0–1167.5) | 34.2 (14.2–56.6) | 5.1 (2.9–9.4) | 3.1 (1.0–7.7) | 17.3 (5.6–65.9) | 10.4 (3.9–34.7) | 10.3 (3.7–25.9) |
Data indicate median and range
aData available for the last consecutive eight ADA-SCID patients